Ego and John Bull: why AZ-Pfizer might falter
This article was originally published in Scrip
So it's official: Pfizer has bid to acquire AstraZeneca. The terms of an offer made back in January 2014, valuing AstraZeneca at just under $100bn, have now been made public (scripintelligence.com, 28 April 2014).
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.